McCord Buys Former GlaxoSmithKline Property in Boston, Advancing Life Sciences Expansion

HOUSTON – (Realty News Report) – The McCord real estate firm has acquired a former GlaxoSmithKline facility near Boston, a property acquisition that advances McCord’s expansion  into the life sciences.

In Houston. McCord is known for its 4,200-acre Generation Park development where McCord is developing a 100,000-SF medical office building.

McCord also recently hired Shawn Cloonan, former Texas Medical Center Chief Operating Officer and life science industry expert, as part of McCord’s leadership team.

“Our approach to real estate is intentional. As we evaluate existing buildings for repositioning or land for new development, we look at how we can positively impact not only the asset, but the surrounding community,” said President of McCord, Ryan McCord. “Boston, just like Houston, is a hub of innovation. Now more than ever it is critical for us to deliver human-centric real estate experiences in these innovation hubs to promote further advancements within the medical and life science fields.”

McCord has opened an office in Boston and the company now calls itself “a Houston and Boston-based opportunistic real estate company.”

MetroWest Life Sciences Cluster

The recently acquired Boston building is called 30 Bearfoot, a 64,736-SF GMP biomanufacturing and research and development facility. (GMP biomanufacturing means Good Manufacturing Practice, a system of standards to ensure high quality standards for pharmaceutical production and other critical manufacturing.)

The 30 Bearfoot building is located Boston’s MetroWest Life Sciences Cluster. McCord acquired 30 Bearfoot from a subsidiary of Alexandria Real Estate Equities who owned the property for 15 years.

“The acquisition sets the stage for McCord’s continued growth in Boston and Houston’s life science spaces,” McCord said.

The MetroWest Life Sciences Cluster, where the McCord building is located, home to leading life science companies such as AbbVie, Boston Scientific, Sanofi Genzyme, and Sunovion.

“The past months have highlighted the importance and complexity of biology,” said Boston-based partner, Quentin Hart. “At McCord, we understand the importance of creating spaces that can facilitate rapid development and production of discoveries that are vital to the future of biomedical advances.”

Sept. 25, 2020 Realty News Report Copyright 2020

File: McCord Buys Former GlaxoSmithKline Property

File: (2) Boston. MetroWest Life Sciences Cluster, AbbVie, Boston Scientific, Sanofi Genzyme, Generation Park. 9-25-20 McCord Buys Former GlaxoSmithKline Property







Clay Development Ad

Related posts

Over 4 Million New Apartments Needed

Realty News Report

Camden Moving HQ to Williams Tower

Realty News Report

RNR Real Estate Briefs – Texas & more

Realty News Report

Leave a Comment